Movement Disorder Unit, Neurology Department, Centre Hospitalier Universitaire (CHU) Grenoble Alpes, University Grenoble Alpes, Grenoble Institut des Neurosciences (GIN), and Institut National de Santé et en Recherche Médicale (INSERM) U1216, Grenoble, France.
Department of Neurology and Institute of Clinical Neuroscience and Medical Psychology, Medical Faculty, Heinrich-Heine University, Düsseldorf, Germany.
Lancet Neurol. 2018 Mar;17(3):223-231. doi: 10.1016/S1474-4422(18)30035-8.
Although subthalamic stimulation is a recognised treatment for motor complications in Parkinson's disease, reports on behavioural outcomes are controversial, which represents a major challenge when counselling candidates for subthalamic stimulation. We aimed to assess changes in behaviour in patients with Parkinson's disease receiving combined treatment with subthalamic stimulation and medical therapy over a 2-year follow-up period as compared with the behavioural evolution under medical therapy alone.
We did a parallel, open-label study (EARLYSTIM) at 17 surgical centres in France (n=8) and Germany (n=9). We recruited patients with Parkinson's disease who were disabled by early motor complications. Participants were randomly allocated (1:1) to either medical therapy alone or bilateral subthalamic stimulation plus medical therapy. The primary outcome was mean change in quality of life from baseline to 2 years. A secondary analysis was also done to assess behavioural outcomes. We used the Ardouin Scale of Behavior in Parkinson's Disease to assess changes in behaviour between baseline and 2-year follow-up. Apathy was also measured using the Starkstein Apathy Scale, and depression was assessed with the Beck Depression Inventory. The secondary analysis was done in all patients recruited. We used a generalised estimating equations (GEE) regression model for individual items and mixed model regression for subscores of the Ardouin scale and the apathy and depression scales. This trial is registered with ClinicalTrials.gov, number NCT00354133. The primary analysis has been reported elsewhere; this report presents the secondary analysis only.
Between July, 2006, and November, 2009, 251 participants were recruited, of whom 127 were allocated medical therapy alone and 124 were assigned bilateral subthalamic stimulation plus medical therapy. At 2-year follow-up, the levodopa-equivalent dose was reduced by 39% (-363·3 mg/day [SE 41·8]) in individuals allocated bilateral subthalamic stimulation plus medical therapy and was increased by 21% (245·8 mg/day [40·4]) in those assigned medical therapy alone (p<0·0001). Neuropsychiatric fluctuations decreased with bilateral subthalamic stimulation plus medical therapy during 2-year follow-up (mean change -0·65 points [SE 0·15]) and did not change with medical therapy alone (-0·02 points [0·15]); the between-group difference in change from baseline was significant (p=0·0028). At 2 years, the Ardouin scale subscore for hyperdopaminergic behavioural disorders had decreased with bilateral subthalamic stimulation plus medical therapy (mean change -1·26 points [SE 0·35]) and had increased with medical therapy alone (1·12 points [0·35]); the between-group difference was significant (p<0·0001). Mean change from baseline at 2 years in the Ardouin scale subscore for hypodopaminergic behavioural disorders, the Starkstein Apathy Scale score, and the Beck Depression Inventory score did not differ between treatment groups. Antidepressants were stopped in 12 patients assigned bilateral subthalamic stimulation plus medical therapy versus four patients allocated medical therapy alone. Neuroleptics were started in nine patients assigned medical therapy alone versus one patient allocated bilateral subthalamic stimulation plus medical therapy. During the 2-year follow-up, two individuals assigned bilateral subthalamic stimulation plus medical therapy and one patient allocated medical therapy alone died by suicide.
In a large cohort with Parkinson's disease and early motor complications, better overall behavioural outcomes were noted with bilateral subthalamic stimulation plus medical therapy compared with medical therapy alone. The presence of hyperdopaminergic behaviours and neuropsychiatric fluctuations can be judged additional arguments in favour of subthalamic stimulation if surgery is considered for disabling motor complications.
German Federal Ministry of Education and Research, French Programme Hospitalier de Recherche Clinique National, and Medtronic.
尽管丘脑下刺激是治疗帕金森病运动并发症的公认方法,但关于行为结果的报告存在争议,这在为丘脑下刺激候选者提供咨询时是一个主要挑战。我们旨在评估在 2 年随访期间,接受丘脑下刺激联合药物治疗的帕金森病患者的行为变化,与单独接受药物治疗的行为演变进行比较。
我们在法国(n=8)和德国(n=9)的 17 个外科中心进行了一项平行、开放标签研究(EARLYSTIM)。我们招募了因早期运动并发症而致残的帕金森病患者。参与者被随机分配(1:1)接受单独药物治疗或双侧丘脑下刺激加药物治疗。主要结果是从基线到 2 年的生活质量平均变化。还进行了二次分析以评估行为结果。我们使用 Ardouin 帕金森病行为量表评估基线和 2 年随访之间的行为变化。使用 Starkstein 淡漠量表评估淡漠,使用贝克抑郁量表评估抑郁。二次分析在所有招募的患者中进行。我们使用广义估计方程(GEE)回归模型对个体项目进行分析,使用混合模型回归对 Ardouin 量表和淡漠和抑郁量表的子分数进行分析。该试验在 ClinicalTrials.gov 上注册,编号为 NCT00354133。主要分析已在其他地方报告;本报告仅介绍二次分析。
2006 年 7 月至 2009 年 11 月期间,共招募了 251 名参与者,其中 127 名分配接受单独药物治疗,124 名分配接受双侧丘脑下刺激加药物治疗。在 2 年随访时,接受双侧丘脑下刺激加药物治疗的个体左旋多巴等效剂量减少了 39%(-363.3mg/天[SE 41.8]),而单独接受药物治疗的个体增加了 21%(245.8mg/天[40.4])(p<0.0001)。在 2 年随访期间,双侧丘脑下刺激加药物治疗可减少神经精神波动(平均变化-0.65 分[SE 0.15]),而单独接受药物治疗则不会改变(-0.02 分[0.15]);两组间的差异有统计学意义(p=0.0028)。在 2 年时,双侧丘脑下刺激加药物治疗的 Ardouin 量表高多巴胺能行为障碍亚量表评分降低(平均变化-1.26 分[SE 0.35]),而单独接受药物治疗的评分增加(1.12 分[0.35]);两组间的差异有统计学意义(p<0.0001)。从基线到 2 年的 Ardouin 量表低多巴胺能行为障碍亚量表评分、Starkstein 淡漠量表评分和贝克抑郁量表评分的平均变化在治疗组之间没有差异。与单独接受药物治疗的患者相比,12 名接受双侧丘脑下刺激加药物治疗的患者停止使用抗抑郁药,而 4 名接受药物治疗的患者停止使用抗抑郁药。与单独接受药物治疗的患者相比,9 名接受药物治疗的患者开始使用神经安定药,而 1 名接受双侧丘脑下刺激加药物治疗的患者开始使用神经安定药。在 2 年随访期间,有 2 名接受双侧丘脑下刺激加药物治疗的患者和 1 名接受单独药物治疗的患者自杀身亡。
在一组患有帕金森病和早期运动并发症的大型队列中,与单独接受药物治疗相比,双侧丘脑下刺激加药物治疗可获得更好的整体行为结果。如果考虑手术治疗致残性运动并发症,则存在高多巴胺能行为和神经精神波动,可以作为支持丘脑下刺激的额外论据。
德国联邦教育与研究部、法国国家临床研究计划医院和美敦力公司。